Certain antibiotics (aminoglycosides) and chemotherapy agents (cisplatin) are also associated with magnesium wasting
Common signs of GLP-1-related body skin changes include: Sagging skin on the upper arms, abdomen, inner thighs, and under the chin Crepey texture a thin, tissue-paper-like appearance, most noticeable on the arms, chest, and knees Rough, uneven texture as skin loses hydration and the outer skin barrier weakens Dullness due to reduced circulation, moisture, and cellular turnover Skin laxity skin that feels loose or less supported as fat volume decreases These changes are not permanent or inevitable and with the right approach, you can meaningfully support your skin's ability to adapt, visibly improving firmness, texture, and hydration over time
Between December 2024 and February 2025, 143 lawsuits were filed as part of the consolidated federal litigation against GLP-1 drug manufacturers
Several studies have been carried out with the goal of deriving new class B GPCR targeting agents 8,9,10,11,12,13
Semaglutide should not be used during pregnancy and there may be potential risks to an unborn baby from exposure to semaglutide during pregnancy
